Bonn-Köln

Infections are specifically deleterious when the immune system of the host is compromised by iatrogenic intervention or as a result of an infectious agent, such as HIV. In principle, there are three strategies to improve the clinical situation: i) Develop better antibiotic treatment (targeting the microbe), ii) Improve the immune status of the patient (targeting the host), and iii) Put existing therapies to better use. The Bonn-Köln partner site has outstanding expertise in all three areas. The research institutes are linked to core units for high-throughput screenings, deep sequencing, and genome-wide siRNA libraries. Translational strategies include gene therapy and oligonucleotide-based approaches to revert immunosuppression. In clinical research, a board-certified centre for infectious diseases provides an ideal infrastructure for training young physicians and for clinical trials. A strong clinical focus is the management of HIV-infected patients (BMBF clinical research group: HIV infection and infections in immunosuppressed patients). Expertise extends to the management of infections in neutropenic patients and the treatment of parasitic infections, and is accompanied by renowned epidemiology. Thus, this consortium bundles the critical mass for a sustained impact on the treatment of infections in the immunocompromised host.

Research at the Bonn-Cologne partner site addresses the following topics:

  • Infection & immunity research
  • Anti-microbial effector mechanisms
  • Translational infectious disease research (target identification, gene therapy, drug research)
  • Clinical trials and research
  • Epidemiology of infection and resistance development, infection control
  • Antituberculosis drug discovery

Partner site speaker
Achim Hörauf (Rheinische Friedrich-Wilhelms-Universität Bonn)

Deputy partner site speaker
Oliver Cornely (University Hospital Cologne)

Partner site manager
Anna Albers (Rheinische Friedrich-Wilhelms-Universität Bonn)
Gisela Kremer (Universität Köln)

Research institutions involved

Rheinische Friedrich-Wilhelms-Universität Bonn

Universitätsklinikum Bonn

Universität zu Köln

Universitätsklinikum Köln

Bundesinstitut für Arzneimittel und Medizinprodukte